Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
02 Maggio 2024 - 2:00PM
Business Wire
Supporting scale-up for early-phase AAV- and
LVV-based gene and gene-modified cell therapy researchers and
developers
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced the launch of its reference materials for adeno
associated virus (AAV) and lentiviral vector (LVV) portfolio,
designed to streamline Cell and Gene Therapy (CGT) research and
development as it scales to Good Manufacturing Practice- (GMP)
quality.
Moving towards a gold standard for reference materials, Charles
River is introducing six AAV reference material serotypes, offering
superior empty and full capsid ratios and high vector genome
concentration (GC/mL), plus five LVV reference material products,
available with different combinations of promoters and reporter
genes. The additional reference materials add to the Company’s
extensive portfolio of plasmid and viral vector contract
development and manufacturing organization (CDMO) offerings,
reinforcing its concept-to-cure commitment to CGT researchers and
developers by enabling partners to navigate the path from early
discovery to commercial.
ASGCT Launch Charles River will officially launch its AAV
and LVV reference materials with supporting case study data during
the American Society of Gene and Cell Therapy (ASGCT) Annual
Meeting, May 7 – 11, 2024, in Baltimore, MD.
Meet the Charles River team at Booth #327 to discuss how
to streamline the CGT research and development process, and explore
various presentations and scientific posters from subject matter
experts, including:
- A cross-functional research and discovery project showcasing
AAV reference material data, AAV Cell Surface Target Profiling
Using Binding and Functional Cell Microarray Screening Technology
(#462), presented by Claire Tebbutt, Group Leader, Discovery
- Wednesday, May 8, 12:00-7:00 p.m.: AAV Vectors – Virology and
Vectorology (Exhibit Hall)
- Closed Automation Enables Quick Fill-Finish of Large-Scale T
Cell Therapy While Maintaining Consistency and Quality of the Final
Product (#867), presented by Min Sung Park, Process Development
Scientist, Cell and Gene Therapy CDMO Services
- Wednesday, May 8, 12:00-7:00 p.m.: Cell Therapy Product
Engineering, Development, and Manufacturing (Exhibit Hall)
- Matrix Approach for Potency Assay Development of Cell and
Gene Therapy Products: A Case Study for AAV Vectors (#1519),
presented by Karen Doucette, Scientific Advisor, Cell and Gene
Therapy CDMO Services
- Friday, May 10, 12:00-7:00 p.m.: AAV Vectors - Product
Development Manufacturing and Approval Considerations (Exhibit
Hall)
To view the full list and to schedule a meeting, visit
criver.com.
Cell and Gene Therapy CDMO Solutions With a strong track
record supporting multiple client programs, Charles River’s viral
vector CDMO center of excellence in Rockville, MD, offers
integrated solutions to support CGT programs from pre-clinical
research to commercial scale.
To learn more about Charles River’s CGT portfolio and gain
real-world insights from a development, manufacturing, and testing
perspective, join an expert roundtable webinar hosted by Human Gene
Therapy, Streamlining Cell and Gene Therapy Scalability: Progress
Towards a Gold Standard, moderated by James Cody, PhD, Associate
Director, Technical Evaluations on May 13, 2024.
To learn more about optimizing the development of gene therapy
products, join the upcoming Charles River webinar, The Roadmap to
Fast-Tracking Gene Therapy Development, on June 4, 2024. The
multi-disciplinary panel will explore in vitro approaches to
optimize and support the development of gene therapy products,
including key considerations and real-world data highlighting
routes to de-risk your therapeutic product.
Approved Quotes
- “This expansion of the CGT product portfolio empowers our
partners to navigate the path from research to commercialization
under one organization, providing a streamlined process. Combined
with Charles River’s established CDMO capabilities, this enables us
to continue to work towards our ultimate goal of delivering safe,
effective therapies to patients faster.” – Kerstin Dolph, Corporate
Senior Vice President, Global Manufacturing, Charles River
- “The launch of Charles River’s AAV and LVV reference materials
portfolio is the latest in a series of enhancements in our CDMO
products and services offerings. We look forward to showcasing our
robust portfolio and supporting data during the ASGCT Annual
Meeting.” – Ramin Baghirzade, PhD, Senior Director, Global Head
Commercial, Gene Therapy CDMO Services, Charles River
About Charles River Charles River provides essential
products and services to help pharmaceutical and biotechnology
companies, government agencies and leading academic institutions
around the globe accelerate their research and drug development
efforts. Our dedicated employees are focused on providing clients
with exactly what they need to improve and expedite the discovery,
early-stage development and safe manufacture of new therapies for
the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502084745/en/
Investor Contact: Todd Spencer Corporate Vice President,
Investor Relations 781.222.6455 todd.spencer@crl.com
Media Contact: Amy Cianciaruso Corporate Vice President,
Chief Communications Officer 781.222.6168
amy.cianciaruso@crl.com
Grafico Azioni Charles River Laboratories (NYSE:CRL)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Charles River Laboratories (NYSE:CRL)
Storico
Da Giu 2023 a Giu 2024